OncLive SOSS

Authors

Meredith Buxton, PhD

Latest:

Meredith Buxton on I-SPY 2 Trial for HER2+ Breast Cancer

Meredith Buxton, PhD, research director, assistant professor, University of California, San Francisco School of Medicine, discusses the I-SPY 2 trial for patients with HER2-positive breast cancer.

Merrick I. Ross, MD

Latest:

Dr. Ross on Biomarker Research Development in Liver Metastasis

Merrick I. Ross, MD, professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses biomarker research development for patients with liver metastasis.

Merrick I. Ross, MD, MD Anderson

Merrick I. Ross, MD, University of Texas MD Anderson Cancer Center

Merrick I. Ross, MD UT MD Anderson Cancer Center

Michael A. Caligiuri, MD

Latest:

Dr. Caligiuri on the Anti-KIR Antibody IPH2101

Michael A. Caligiuri, MD, CEO, The James Cancer Hospital Solove Research Institute, director, Comprehensive Cancer Center, Ohio State University, discusses the anti-KIR antibody IPH2101 in myeloma and leukemia.

Michael A. Carducci, MD, FACP, Sidney Kimmel Comprehensive Cancer Center of Johns Hopkins Hospital

Latest:

Dr. Carducci on the Ongoing CAPItello-280 Trial in mCRPC

Michael A. Carducci, MD, discusses the significance of two ongoing clinical trials in prostate cancer: the phase 3 CAPItello-280 trial (NCT05348577) and phase 3 INDICATE study (EA8191; NCT04423211).

Michael A. Choti, MD

Latest:

Dr. Choti on Pursuing Chemotherapy Following Tumor Resection in Advanced CRC

Michael A. Choti, MD, discusses pursuing chemotherapy following tumor resection in advanced colorectal cancer.

Michael A. Davies, MD, PhD, MD Anderson Cancer Center

Michael A. Davies, MD, PhD, University of Texas MD Anderson Cancer Center

Michael A. Davies, MD, PhD UT MD Anderson Cancer Center

Michael A. Kolodziej, MD

Latest:

Understanding the Implications of Mandatory Vendor Imposition in Oncology

The rising costs of healthcare have caused payers to analyze spending and take measures to contain costs.

Michael A. Morse, MD

Latest:

Closing Thoughts on Advanced HCC and Highlights from ASCO GI 2023

Closing out this discussion, experts share their final thoughts on advanced HCC treatments and key data presented at the 2023 ASCO Gastrointestinal Cancers Symposium.

Michael A. Morse, MD, Duke Cancer Institute

Michael A. Morse, MD, MHS, FACP, Duke Cancer Institute

Michael A. Poch, MD

Latest:

Dr. Poch on Nivolumab as a Treatment for Patients With Bladder Cancer

Michael A. Poch, MD, urologist and assistant member at Moffitt Cancer Center, discusses the potential of nivolumab (Opdivo) as a treatment for patients with metastatic bladder cancer.

Michael A. Postow, MD

Latest:

Dr Postow on the Potential Role for Triplet Regimens in Melanoma

Michael A. Postow, MD, discusses the potential role for triplet regimens in melanoma management.

Michael A. Postow, MD, Memorial Sloan Kettering Cancer Center

Michael A. Rodriguez, MD, MPH

Latest:

Cervical Cancer Screening Overuse and Underuse: Patient and Physician Factors

For a decade, US medical professional organizations and the US Preventive Services Task Force have suggested that low-risk women (history of multiple normal Papanicolaou [pap] tests, age over 30 years) receive cervical cancer screening every 3 years as part of routine preventive services.

Michael A. Samuels, MD

Latest:

Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

This study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.